Precision Biologics’ CEO, Dr. Philip M. Arlen, to Chair Therapeutic Cancer Vaccine Program, and lead...
Genetic Engineering and Biotechnology News (GEN) news article highlights Precision Biologics, Inc., August 1, 2024...
NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....
This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO,...
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION:...
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with...
First international congress of BIOIMMUNOTHERAPY OF CANCER An International multidisciplinary meeting 12-13-14 APRILE 2019 REGGIO CALABRIA ITALY Palazzo della Provincia, Sala...
